Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting.

ENPNewswire-October 19, 2021--Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting

(C)2021 ENPublishing - http://www.enpublishing.co.uk

Release date- 18102021 - MARLBOROUGH, Mass. - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, announced that new data suggesting a systemic immune response can be generated with its lead clinical product candidate, PH-762, after local administration. These data will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, being held in Washington, D.C. on November 10-14, 2021.

Presentation Details are as follows:

Title: Locally administered immunotherapy self-delivering RNAi PH-762 results in abscopal clearance of untreated distal tumors, suggesting systemic immune response, in a murine hepatocarcinoma model

Abstract Number: 869

Author: Benjamin Cuiffo, et al.

Time and Date: 7:00 am - 8:30 pm ET on 11/12/2021

Location: Poster Hall - Hall E

Poster presentations will be accessible in person and virtually. Posters will released on the SITC website at 7:00 am ET on November 12, 2021 and will also be made available on the 'Investors - Events and Presentations' section of the Company's website.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as 'intends,' 'believes,' 'anticipates,' 'indicates,' 'plans,' 'expects,' 'suggests,' 'may,' 'would,' 'should,' 'potential,' 'designed to,' 'will,' 'ongoing,'...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT